Novo Nordisk will present 12 abstracts at The Liver Meeting, including an electronic health record comparison of semaglutide 2.4 mg against resmetirom in adults with MASH drawn from 30 US health systems. The analysis tracks liver enzymes, weight, HbA1c, platelets and lipids at three and six months, but patients were not randomized, so the results describe associations rather than causal effects. A post-hoc look at ESSENCE participants with BMI below 27 extends the question to MASH occurring without obesity.
Key Points
- Semaglutide and resmetirom compared in 5,158 non-randomized MASH patients
- Endpoints include liver enzymes, weight, HbA1c, platelets, lipids
- Nearly 90% of an estimated 250 million MASH cases undiagnosed
Longevity Analysis
MASH sits at the intersection of impaired fat handling, insulin resistance and cardiovascular risk, which is why a liver endpoint functions as a proxy for broader metabolic trajectory. The disease progresses silently for years, and the rising liver enzymes that eventually flag it are a late signal rather than an early one — detection depends on interpreting mildly abnormal blood chemistry as meaningful rather than incidental. Pharmacological options are expanding, but the comparison here reflects routine prescribing patterns rather than controlled allocation, and sustained benefit still depends on whether treatment and metabolic correction are maintained long enough for hepatic architecture to recover.
Original published by Longevity.Technology, by Kyle Umipig.